Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26304963  

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

George Giotopoulos | Louise van der Weyden | Hikari Osaki | Alistair G Rust | Paolo Gallipoli | Eshwar Meduri | Sarah J Horton | Wai-In Chan | Donna Foster | Rab K Prinjha | John E Pimanda | Daniel G Tenen | George S Vassiliou | Steffen Koschmieder | David J Adams | Brian J P Huntly
The Journal of experimental medicine | 2015

The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent on BCR-ABL, additional mutations are required for progression to BC. However, the identity of these mutations and the pathways they affect are poorly understood, hampering our ability to identify therapeutic targets and improve outcomes. Here, we describe a novel mouse model that allows identification of mechanisms of BC progression in an unbiased and tractable manner, using transposon-based insertional mutagenesis on the background of chronic phase CML. Our BC model is the first to faithfully recapitulate the phenotype, cellular and molecular biology of human CML progression. We report a heterogeneous and unique pattern of insertions identifying known and novel candidate genes and demonstrate that these pathways drive disease progression and provide potential targets for novel therapeutic strategies. Our model greatly informs the biology of CML progression and provides a potent resource for the development of candidate therapies to improve the dismal outcomes in this highly aggressive disease.

Pubmed ID: 26304963

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Wellcome Trust, United Kingdom
    Id: 095663
  • Agency: Cancer Research UK, United Kingdom
    Id: 13031
  • Agency: Worldwide Cancer Research, United Kingdom
    Id: 14-1069
  • Agency: Medical Research Council, United Kingdom
    Id: MR/M010392/1

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BioLegend (tool)

RRID:SCR_001134

Commercial antibody supplier and developer for biomedical research. These products are compatible with use in flow cytometry and mass cytometry, immunoprecipitation and chip, western blotting, immunofluorescence microscopy, and quantitative multiplexing.

View all literature mentions

FlowJo (tool)

RRID:SCR_008520

Software for single-cell flow cytometry analysis. Its functions include management, display, manipulation, analysis and publication of the data stream produced by flow and mass cytometers.

View all literature mentions

QIAGEN (tool)

RRID:SCR_008539

A commercial organization which provides assay technologies to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.

View all literature mentions

LIMMA (tool)

RRID:SCR_010943

Software package for the analysis of gene expression microarray data, especially the use of linear models for analyzing designed experiments and the assessment of differential expression.

View all literature mentions

ComBat (tool)

RRID:SCR_010974

Adjusting batch effects in microarray expression data using Empirical Bayes methods.

View all literature mentions

BLAT (tool)

RRID:SCR_011919

Software designed to quickly find sequences of 95% and greater similarity of length 25 bases or more.

View all literature mentions

lumi (tool)

RRID:SCR_012781

Software that provides an integrated solution for the Illumina microarray data analysis.

View all literature mentions

Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions

HEK293T (tool)

RRID:CVCL_0063

Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

FVB/NJ (tool)

RRID:IMSR_JAX:001800

Mus musculus with name FVB/NJ from IMSR.

View all literature mentions